In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights to watch out for.

Which ones look promising, which might be duds?

You can’t always tell from abstract titles, even if the trial has been selected for oral presentation so right now we’re flying by the seat of our pants somewhat if the top line result hasn’t been formally announced yet.

Our selections include a variety of different modalities such as monoclonal antibodies, cell therapies, bispecific antibodies, fusion proteins, and even small molecules across a wide range of targets…

To continue reading our latest discussion on oncology new product development plus commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by